NNNN Stock Forecast: Anbio Biotechnology Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 14 Sept 2026 — in the weakest quartile.
NNNN stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Anbio Biotechnology on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (85): Sales and profits are climbing, and climbing faster than before.
Momentum (1): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
NNNN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NNNN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NNNN appears on the weeks it earns a place.
NNNN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Sept 2026, Anbio Biotechnology returned −85.8% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NNNN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Anbio Biotechnology (NNNN) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 40.7×
- Price / sales
- 31.0×
- Price / book
- 8.9×
- EV / EBITDA
- 48.6×
Cheaper than 17% of US stocks
Cheaper than 7% of US stocks
Cheaper than 10% of US stocks
Cheaper than 5% of US stocks
- Revenue growth (YoY)
- 73.9%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 59.1%
- Net margin
- 74.1%
Higher than 90% of US stocks
Higher than 98% of US stocks
Higher than 98% of US stocks
- Return on equity
- 27.0%
- Return on assets
- 14.7%
- Dividend yield
- —
Higher than 86% of US stocks
Higher than 97% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Anbio Biotechnology (NNNN) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Anbio Biotechnology has a market value of $268.2M and an enterprise value of $256.3M.
Trailing P/E: 40.7×.
Anbio Biotechnology employs 27 people.
Data provided by Twelve Data
NNNN vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Anbio Biotechnology — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about NNNN stock
How does Ticker Nerd's model rank NNNN?
As at 14 Sept 2026, Anbio Biotechnology ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).
What is the NNNN stock forecast for 2030?
No analyst covering Anbio Biotechnology publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NNNN are extrapolating price history, which says nothing about the business.
How has NNNN stock performed over the past year?
Anbio Biotechnology returned -85.8% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Anbio Biotechnology do?
Anbio Biotechnology Ltd is a medical device company focused on in vitro diagnostics. Anbio Biotechnology develops and supplies diagnostic products for over-the-counter use, point-of-care testing, and laboratory applications, serving healthcare providers and patients in multiple settings.
About Anbio Biotechnology.
Anbio Biotechnology Ltd is a medical device company focused on in vitro diagnostics. Anbio Biotechnology develops and supplies diagnostic products for over-the-counter use, point-of-care testing, and laboratory applications, serving healthcare providers and patients in multiple settings. Its portfolio spans several testing technologies, including fluorescence immunoassay, chemiluminescence immunoassay, lateral flow immunoassay, loop-mediated isothermal amplification, dry chemistry, and real-time polymerase chain reaction. The company also offers rapid antigen test kits for respiratory infections and other diagnostic needs. With a global presence across major international markets, Anbio Biotechnology plays a role in expanding access to fast, decentralized diagnostic tools used in infectious disease detection and broader biomarker testing.
27 employees · Germany · https://www.anbiobiotechnology.com